Document is current
Any future updates will be listed below
-
Authors
Phadke, Manali S
Li, Jiannong
Chen, Zhihua
Rodriguez, Paulo C
Mandula, Jessica K
Karapetyan, Lilit https://orcid.org/0000-0001-8530-0907
Forsyth, Peter A
Chen, Y Ann
Smalley, Keiran S M https://orcid.org/0000-0003-1089-9307
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05704647 at ClinicalTrials.govnct05704647 at ClinicalTrials.govDocuments that mention this clinical trial
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models
https://doi.org/10.1136/jitc-2023-007239
Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).
https://doi.org/10.1200/jco.2023.41.16_suppl.tps9605
Real-world outcomes in patients with melanoma brain metastasis: a US multisite retrospective chart review study of systemic treatments
https://doi.org/10.1136/bmjopen-2024-091098
Documents that mention this clinical trial
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models
https://doi.org/10.1136/jitc-2023-007239
Phase II study of nivolumab (nivo) in combination with relatlimab (rela) in patients (pts) with active melanoma brain metastases (MBM).
https://doi.org/10.1200/jco.2023.41.16_suppl.tps9605
Real-world outcomes in patients with melanoma brain metastasis: a US multisite retrospective chart review study of systemic treatments
https://doi.org/10.1136/bmjopen-2024-091098
-
Funding
Funding for this research was provided by:
Melanoma Research Foundation (N/A)
National Institutes of Health (R01 CA236034)
National Institutes of Health (R21 CA252634)
National Cancer Institute (R01 CA262483)
National Cancer Institute (R21 CA256289)
Florida Department of Health (22B04)
The Department of Defense (W81XWH1910675)
- License Information
